You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma

 

Online download statistics by month:

Online download statistics by month: May 2020 to July 2025

AbstractFullPdf
May 2020185185212
Jun 2020283283194
Jul 202019419455
Aug 202016016087
Sep 202014014091
Oct 2020141141130
Nov 202015315268
Dec 202014514577
Jan 202118218283
Feb 202116716783
Mar 202117117199
Apr 202125325386
May 202115615671
Jun 202114214288
Jul 2021151151100
Aug 2021184187119
Sep 2021159159110
Oct 2021158160105
Nov 2021190190139
Dec 2021171175116
Jan 2022152159100
Feb 202215416199
Mar 2022211219146
Apr 2022162170122
May 202214915299
Jun 202214515282
Jul 2022197206120
Aug 2022174176107
Sep 2022135140127
Oct 2022215222146
Nov 2022189192131
Dec 202217717883
Jan 2023178179103
Feb 2023241241137
Mar 2023171174104
Apr 202313813985
May 202314314580
Jun 202312713062
Jul 202315615682
Aug 202313213296
Sep 202314715167
Oct 2023210211103
Nov 202333033196
Dec 2023183183115
Jan 202411912085
Feb 202413713889
Mar 2024218220153
Apr 202414214298
May 202413713787
Jun 202411111179
Jul 2024137143240
Aug 2024140142175
Sep 202411111181
Oct 2024111112254
Nov 2024177179113
Dec 2024196198134
Jan 2025138138108
Feb 2025203203156
Mar 2025158158133
Apr 2025192194112
May 2025133133102
Jun 2025454528
Jul 2025110
Total10307104176832